Life Science Investing Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Life Science Investing Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
Life Science Investing Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
Life Science Investing Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
Life Science Investing Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
Life Science Investing Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
Life Science Investing Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
Life Science Investing Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
Life Science Investing Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Life Science Investing Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
